https://www.selleckchem.com/products/fhd-609.html
There was a slightly increased risk of respiratory and urinary tract infections treated in primary care among secukinumab users compared to ustekinumab users (HR 1.22, 95% CI 1.03-1.43). Non-significant differences in estimated risk of severe respiratory and urinary tract infections (HR 0.96, 95% CI 0.57-1.61) and candidiasis (HR 1.80, 95% CI 0.84-3.84) treated in the hospital setting were observed. We observed a slightly increased risk of respiratory and urinary tract infections treated in primary care among secukinumab users compared
Like
Comment
Share
